Evidence method
Level · gp.fundamentals.debt_to_revenue
254.68% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ADPT · Mar 31, 2025
Adaptive Biotechnologies Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-25-061897General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.40% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-54.31% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
25.24% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
16.56% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
67.62% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-56.45% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
46.15% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
23.16% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20217/8 normalizedLevel 3Dec 31, 20217/8 normalizedLevel 3Mar 31, 20227/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/9 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/9 normalizedLevel 3Mar 31, 20258/9 normalizedLevel 3Jun 30, 20258/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 74.48%
- Current
- 254.68%
- Delta
- 180.20%
- Previous
- 2.05%
- Current
- 2.40%
- Delta
- 0.35%
- Previous
- -53.20%
- Current
- -54.31%
- Delta
- -1.11%
- Previous
- 5.10%
- Current
- 25.24%
- Delta
- 20.14%
- Previous
- 4.72%
- Current
- 16.56%
- Delta
- 11.84%
- Previous
- 59.72%
- Current
- 67.62%
- Delta
- 7.90%
- Previous
- -90.83%
- Current
- -56.45%
- Delta
- 34.38%
- Previous
- 57.53%
- Current
- 46.15%
- Delta
- -11.38%
- Previous
- 29.96%
- Current
- 23.16%
- Delta
- -6.79%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ADPT Fundamental State →Has State · Adaptive Biotechnologies Corp →Transitioned To · ADPT Fundamental State →Transitioned To · ADPT BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · ADPT CAPEX_INTENSITY_INCREASED →Transitioned To · ADPT CASH_GENERATION_DECREASED →Transitioned To · ADPT GROWTH_INCREASED →Transitioned To · ADPT INVENTORY_PRESSURE_INCREASED →Transitioned To · ADPT MARGIN_INCREASED →Transitioned To · ADPT PROFITABILITY_INCREASED →Transitioned To · ADPT R_AND_D_INTENSITY_DECREASED →Transitioned To · ADPT SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.